What is the share price of Dishman Carbogen Amcis Ltd (DCAL) today?
The share price of DCAL as on 5th February 2026 is ₹210.32. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dishman Carbogen Amcis Ltd (DCAL) share?
The past returns of Dishman Carbogen Amcis Ltd (DCAL) share are- Past 1 week: 3.61%
- Past 1 month: -17.45%
- Past 3 months: -29.33%
- Past 6 months: -15.74%
- Past 1 year: -13.94%
- Past 3 years: 153.25%
- Past 5 years: 69.54%
What are the peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL)?
The peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL) include:What is the market cap of Dishman Carbogen Amcis Ltd (DCAL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dishman Carbogen Amcis Ltd (DCAL) is ₹3297.46 Cr as of 5th February 2026.What is the 52 week high and low of Dishman Carbogen Amcis Ltd (DCAL) share?
The 52-week high of Dishman Carbogen Amcis Ltd (DCAL) is ₹321.95 and the 52-week low is ₹178.What is the PE and PB ratio of Dishman Carbogen Amcis Ltd (DCAL) stock?
The P/E (price-to-earnings) ratio of Dishman Carbogen Amcis Ltd (DCAL) is 1017.74. The P/B (price-to-book) ratio is 0.57.Which sector does Dishman Carbogen Amcis Ltd (DCAL) belong to?
Dishman Carbogen Amcis Ltd (DCAL) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Dishman Carbogen Amcis Ltd (DCAL) shares?
You can directly buy Dishman Carbogen Amcis Ltd (DCAL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dishman Carbogen Amcis Ltd
DCAL Share Price
210.320.40% (-0.84)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
DCAL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
DCAL Performance & Key Metrics
DCAL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.76 | 0.57 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.40 | 5.62 | 0.61% |
DCAL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
DCAL Company Profile
Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing
DIVISLAB
PE Ratio
74.41
74.41
1Y Return
0.29%
0.29%
Buy Reco %
56.00
56.00
SYNGENE
PE Ratio
37.20
37.20
1Y Return
38.41%
38.41%
Buy Reco %
83.33
83.33
AARTIPHARM
PE Ratio
26.07
26.07
1Y Return
23.11%
23.11%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
28.50
28.50
1Y Return
8.10%
8.10%
Buy Reco %
0.00
0.00
PE Ratio
59.46
59.46
1Y Return
18.71%
18.71%
Buy Reco %
0.00
0.00
DCAL Sentiment Analysis
DCAL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
DCAL Stock Summary · November 2025
The company is poised for significant growth, driven by a robust project pipeline and increased customer interest, particularly in its French facility and the Bavla site. Despite a recent decline in revenue due to order deferments, strong EBITDA growth and operational efficiencies have been achieved, particularly in high-margin Phase 3 projects. The transition to a unified ERP system aims to enhance operational performance and transparency, while strategic collaborations, including with Celonic, are expected to bolster revenue. Challenges remain, such as low utilization rates at certain sites and rising interest costs, but management remains optimistic about achieving long-term financial goals, including a targeted 25% Return on Capital Employed over the next few years.
DCAL Stock Growth Drivers
DCAL Stock Growth Drivers
6Operational Performance and Achievements
The company has successfully obtained a GMP certificate for its French subsidiary, leading to an
Collaborations and Partnerships
The company has entered into a collaboration with Celonic to enhance its antibody production capabilities,
DCAL Stock Challenges
DCAL Stock Challenges
5Decline in Revenue
The company reported a decrease in revenue for the quarter ending September 30, 2025, with
Increased Interest Costs
There has been a notable increase in interest costs, rising from INR 120 crores to
DCAL Forecast
DCAL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
DCAL
DCAL
Income
Balance Sheet
Cash Flow
Annual Normal View
DCAL Income Statement
DCAL Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,739.82 | 1,740.48 | 2,112.42 | 2,088.06 | 1,950.48 | 2,184.11 | 2,440.69 | 2,643.98 | 2,733.18 | 2,844.33 | ||||||||||
Raw Materials | 329.58 | 402.19 | 378.01 | 476.38 | 434.77 | 460.50 | 630.40 | 601.21 | 592.96 | 2,255.87 | ||||||||||
| Power & Fuel Cost | 49.47 | 48.33 | 56.14 | 60.26 | 41.87 | 62.73 | 87.83 | 104.31 | 92.26 | |||||||||||
| Employee Cost | 596.02 | 625.40 | 714.64 | 762.27 | 872.91 | 981.49 | 1,029.86 | 1,208.16 | 1,293.57 | |||||||||||
| Selling & Administrative Expenses | 147.69 | 136.29 | 190.73 | 124.58 | 113.81 | 147.71 | 197.66 | 206.07 | 197.13 | |||||||||||
| Operating & Other expenses | 138.47 | 37.23 | 167.18 | 122.55 | 196.60 | 171.53 | 183.12 | 215.66 | 84.75 | |||||||||||
EBITDA | 478.59 | 491.04 | 605.72 | 542.02 | 290.52 | 360.15 | 311.82 | 308.57 | 472.51 | 588.46 | ||||||||||
| Depreciation/Amortization | 213.50 | 211.42 | 240.38 | 282.87 | 307.94 | 307.59 | 280.72 | 310.86 | 293.74 | 328.99 | ||||||||||
| PBIT | 265.09 | 279.62 | 365.34 | 259.15 | -17.42 | 52.56 | 31.10 | -2.29 | 178.77 | 259.47 | ||||||||||
| Interest & Other Items | 49.01 | 48.83 | 56.55 | 61.95 | 47.61 | 56.81 | 85.69 | 119.97 | 159.46 | 173.00 | ||||||||||
| PBT | 216.08 | 230.79 | 308.79 | 197.20 | -65.03 | -4.25 | -54.59 | -122.26 | 19.31 | 86.47 | ||||||||||
| Taxes & Other Items | 70.65 | 76.22 | 98.46 | 38.69 | 100.10 | -22.26 | -24.79 | 31.19 | 16.07 | -32.33 | ||||||||||
| Net Income | 145.43 | 154.57 | 210.33 | 158.51 | -165.13 | 18.01 | -29.80 | -153.45 | 3.24 | 118.80 | ||||||||||
| EPS | 0.00 | 19.15 | 13.03 | 9.96 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 7.58 | ||||||||||
| DPS | 1.20 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DCAL Company Updates
FY 2026FY 2026
Investor Presentation
Feb 4PDF
Nov 5PDF
Sep 17PDF
+2 more
DCAL Stock Peers
DCAL Past Performance & Peer Comparison
DCAL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dishman Carbogen Amcis Ltd | 1,017.74 | 0.57 | — |
| Divi's Laboratories Ltd | 74.41 | 10.89 | 0.49% |
| Syngene International Ltd | 37.20 | 3.91 | 0.27% |
| Aarti Pharmalabs Ltd | 26.07 | 3.57 | 0.64% |
DCAL Stock Price Comparison
Compare DCAL with any stock or ETFCompare DCAL with any stock or ETF
DCAL
DCAL Holdings
DCAL Shareholdings
DCAL Promoter Holdings Trend
DCAL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
DCAL Institutional Holdings Trend
DCAL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
DCAL Shareholding Pattern
DCAL Shareholding Pattern
DCAL Shareholding History
DCAL Shareholding History
Foreign Institutions
Mutual Funds Invested in DCAL
Mutual Funds Invested in DCAL
No mutual funds holding trends are available
Top 5 Mutual Funds holding Dishman Carbogen Amcis Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1038% | Percentage of the fund’s portfolio invested in the stock 0.70% | Change in the portfolio weight of the stock over the last 3 months -0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/96 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1645% | Percentage of the fund’s portfolio invested in the stock 0.21% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 182/255 (+22) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0008% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 278/759 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing DCAL stock
smallcases containing DCAL stock
Looks like this stock is not in any smallcase yet.
DCAL Events
DCAL Events
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
DCAL Upcoming Dividends
DCAL Upcoming Dividends
No upcoming dividends are available
DCAL Past Dividends
DCAL Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Sep 12, 2019
DCAL Stock News & Opinions
DCAL Stock News & Opinions
Articles & Videos
Earnings
Dishman Carbogen Amcis reports consolidated net loss of Rs 12.97 crore in the December 2025 quarter
Net loss of Dishman Carbogen Amcis reported to Rs 12.97 crore in the quarter ended December 2025 as against net profit of Rs 4.63 crore during the previous quarter ended December 2024. Sales rose 5.49% to Rs 719.80 crore in the quarter ended December 2025 as against Rs 682.34 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales719.80682.34 5 OPM %15.7120.54 - PBDT73.9896.98 -24 PBT-10.4425.01 PL NP-12.974.63 PL Powered by Capital Market - Live
1 day agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to declare Quarterly Results
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Dishman Carbogen Amcis allots NCDs aggregating to Rs 50 cr
Dishman Carbogen Amcis has allotted 5,000 Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures of Rs 1 lakh each aggregating to Rs 50 crore on private placement basis on 20 January 2026. Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to convene board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 27 December 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Dishman Carbogen Amcis consolidated net profit rises 97.25% in the September 2025 quarter
Net profit of Dishman Carbogen Amcis rose 97.25% to Rs 65.27 crore in the quarter ended September 2025 as against Rs 33.09 crore during the previous quarter ended September 2024. Sales declined 17.29% to Rs 652.65 crore in the quarter ended September 2025 as against Rs 789.04 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales652.65789.04 -17 OPM %22.8118.65 - PBDT114.67117.17 -2 PBT30.5445.08 -32 NP65.2733.09 97 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to conduct board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 4 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to convene AGM
Dishman Carbogen Amcis announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis schedules AGM
Dishman Carbogen Amcis announced that the Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Dishman Carbogen Amcis Ltd Spikes 4.86%
Dishman Carbogen Amcis Ltd rose 4.86% today to trade at Rs 254.7. The BSE Healthcare index is up 0.57% to quote at 44074.27. The index is down 1.71 % over last one month. Among the other constituents of the index, Apollo Hospitals Enterprise Ltd increased 4.33% and Alkem Laboratories Ltd added 3.98% on the day. The BSE Healthcare index went up 7.42 % over last one year compared to the 1.95% surge in benchmark SENSEX. Dishman Carbogen Amcis Ltd has added 1.47% over last one month compared to 1.71% fall in BSE Healthcare index and 2.14% drop in the SENSEX. On the BSE, 4125 shares were traded in the counter so far compared with average daily volumes of 6651 shares in the past one month. The stock hit a record high of Rs 307.8 on 11 Dec 2024. The stock hit a 52-week low of Rs 161.35 on 07 Oct 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 23.41 crore in the June 2025 quarter
Net profit of Dishman Carbogen Amcis reported to Rs 23.41 crore in the quarter ended June 2025 as against net loss of Rs 77.57 crore during the previous quarter ended June 2024. Sales rose 35.18% to Rs 708.05 crore in the quarter ended June 2025 as against Rs 523.78 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales708.05523.78 35 OPM %19.875.53 - PBDT122.67-1.53 LP PBT41.32-72.12 LP NP23.41-77.57 LP Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.53%, vs industry avg of 7.49%
Over the last 5 years, market share decreased from 17.14% to 13.77%
Over the last 5 years, net income has grown at a yearly rate of -54.07%, vs industry avg of 8.2%